160 East 34th Street
New York, NY 10016
Dr. Abraham Chachoua specializes in the treatment of thoracic malignancies. Originally trained in Melbourne, Australia, he came to NYU to complete a research fellowship in medical oncology and was the recipient of an American Cancer Society career development award to evaluate the role of immune modulation in the treatment of solid tumors.
He has been involved in a number of clinical trials for the treatment of non small cell lung cancer.
Dr. Chachoua has a particular interest in the study of novel targeted therapies, how to use them earlier in the course of the illness and how to combine them with conventional chemotherapy for the treatment of advanced thoracic cancers. Among other interests he also attempts to use unique approaches for the integration of multimodality approaches for the treatment of locally advanced lung cancer.
Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy
Becker, Daniel J; Wisnivesky, Juan P; Grossbard, Michael L; Chachoua, Abraham; Camidge, D Ross; Levy, Benjamin P. Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy. Clinical lung cancer. 2016 Oct 5;:?-? (2383632)
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma
Pass, Harvey I; Goparaju, Chandra; Espin-Garcia, Osvaldo; Donington, Jessica; Carbone, Michele; Patel, Devalben; Chen, Zhuo; Feld, Ronald; Cho, John; Gadgeel, Shirish; Wozniak, Antoinette; Chachoua, Abraham; Leighl, Natasha; Tsao, Ming-Sound; de Perrot, Marc; Xu, Wei; Liu, Geoffrey. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Journal of thoracic oncology. 2016 Jun;11(6):900-909 (1965372)
Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery
Shin, Samuel M; Cooper, Benjamin T; Chachoua, Abraham; Butler, James; Donahue, Bernadine; Silverman, Joshua S; Kondziolka, Douglas. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. Journal of neuro-oncology. 2016 Feb;126(3):483-491 (1825672)
RICTOR amplification defines a novel subset of lung cancer patients who may benefit from treatment with mTOR1/2 inhibitors
Cheng, Haiying; Zou, Yiyu; Ross, Jeffrey S; Wang, Kai; Liu, Xuewen; Halmos, Balazs; Ali, Siraj M; Liu, Huijie; Verma, Amit; Montagna, Cristina; Chachoua, Abraham; Goel, Sanjay; Schwartz, Edward L; Zhu, Changcheng; Shan, Jidong; Yu, Yiting; Gritsman, Kira; Yelensky, Roman; Lipson, Doron; Otto, Geoff; Hawryluk, Matthew; Stephens, Philip J; Miller, Vincent A; Piperdi, Bilal; Perez-Soler, Roman. RICTOR amplification defines a novel subset of lung cancer patients who may benefit from treatment with mTOR1/2 inhibitors. Cancer discovery. 2015 Dec;5(12):1262-1270 (1779172)
Reactivation of pulmonary tuberculosis during cancer treatment
Jacobs, Ramon E A; Gu, Ping; Chachoua, Abraham. Reactivation of pulmonary tuberculosis during cancer treatment. International journal of mycobacteriology. 2015 Dec;4(4):337-340 (2024482)